AstraZeneca, GB0009895292

AstraZeneca stock: FDA grants priority review to Sone-Ve

Published on 11/20/2026 at 17:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock is in focus after the FDA granted Sone-Ve priority review. A US decision is expected in the second quarter of 2027.

Next step for Sone-Ve

  • The FDA accepted AstraZeneca's biologics license application for second-line and later treatment of advanced gastric, gastroesophageal junction and esophageal cancers.
  • The application covers tumors with CLDN18.2 expression in at least 25 percent of tumor cells, while the regulatory decision is expected in the second quarter of 2027.
  • Phase III CLARITY-Gastric01 results underpin the application, with a reported overall-survival benefit versus investigator's choice of therapy.
AstraZeneca, GB0009895292, Illustration mit AI erstellt.

AstraZeneca said on Thursday, November 19, that the US Food and Drug Administration accepted its biologics license application for sonesitatug vedotin, or Sone-Ve, and granted it Priority Review. The application covers second-line and later treatment of locally advanced or metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma with CLDN18.2 expression in at least 25 percent of tumor cells, according to the company's press release.

Regulatory milestone in oncology

The FDA action shortens the expected review path for a potential new targeted treatment in a setting with limited options. AstraZeneca said the Prescription Drug User Fee Act action date is anticipated in the second quarter of 2027.

The application is based on results from the Phase III CLARITY-Gastric01 trial. AstraZeneca reported that Sone-Ve reduced the risk of death by 42 percent versus investigator's choice of therapy, with median overall survival of 10.6 months compared with 6.4 months. The company said no new safety signals were identified.

What changed for investors

The regulatory step adds a fresh oncology catalyst to AstraZeneca's pipeline and creates a defined milestone for investors to monitor in 2027. Regulatory applications for Sone-Ve are also under review in the European Union, China and several other countries, according to the company.

AstraZeneca stock last quoted at 160.08 euros on Lang & Schwarz at 17:03 CET on Friday, November 20, 2026. That was 3.10 percent below the 165.20-euro quote recorded in the company's November 17 market report, separating the move since that report from the day's trading context.

AstraZeneca PLC at a glance

  • ISIN: GB0009895292
  • WKN: 886455
  • Frankfurt ticker: ZEG
  • Quote: 160.08 euros on Lang & Schwarz at 17:03 CET on Friday, November 20, 2026

The UK equity market can be followed in Current market reports.

More news and analyses on AstraZeneca stock.

Disclaimer...
en | GB0009895292 | ASTRAZENECA | boerse | 70540564 | bgmi